[EN] PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PYRROLO[2,3-B]PYRIDINE CDK9 KINASE
申请人:ABBVIE INC
公开号:WO2014139328A1
公开(公告)日:2014-09-18
Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).
본 발명은 하기 화학식 I을 갖는 카복사미드 및 설폰아미드, 및 이의 약제학적으로 허용되는 염 및 용매화물을 제공한다. 본 발명은 또한, SMYD 단백질, 예를 들어, SMYD3 또는 SMYD2의 차단에 반응을 보이는 장애를 치료하기 위한 화학식 I의 화합물의 용도에 관한 것이다. 본 발명의 화합물은 암을 치료하는데 특히 유용하다: [화학식 I] 상기 식에서, A, Y, B, X, 및 Z는 명세서에 기술된 바와 같이 정의된다.
[EN] PYRAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLYL PYRIMIDINYLAMINE EN TANT QU'INHIBITEURS DE CDK2
申请人:INCYTE CORP
公开号:WO2020180959A1
公开(公告)日:2020-09-10
The present application provides pyrazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Disclosed are compounds of Formula (IIa),
wherein R
1
, R
2
, R
3A
, R
3B
, R
3C
, R
3D
, R
3E
, and R
4
are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).
[EN] COMPOUND AS CDK KINASE INHIBITOR AND USE THEREOF<br/>[FR] COMPOSÉ UTILE EN TANT QU'INHIBITEUR DE KINASE DÉPENDANTE DES CYCLINES ET SON UTILISATION<br/>[ZH] 用作CDK激酶抑制剂的化合物及其应用